Strs Ohio Grows Stake in Elanco Animal Health Incorporated $ELAN

Strs Ohio increased its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 848.2% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 111,770 shares of the company’s stock after purchasing an additional 99,982 shares during the period. Strs Ohio’s holdings in Elanco Animal Health were worth $2,675,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Brown Miller Wealth Management LLC acquired a new stake in Elanco Animal Health in the 1st quarter worth about $376,000. Pictet Asset Management Holding SA raised its holdings in shares of Elanco Animal Health by 5.7% during the first quarter. Pictet Asset Management Holding SA now owns 80,839 shares of the company’s stock valued at $1,934,000 after acquiring an additional 4,372 shares during the last quarter. Louisiana State Employees Retirement System acquired a new position in shares of Elanco Animal Health during the first quarter valued at approximately $3,448,000. Ritholtz Wealth Management purchased a new position in shares of Elanco Animal Health in the first quarter valued at approximately $302,000. Finally, Friedenthal Financial purchased a new position in shares of Elanco Animal Health in the first quarter valued at approximately $1,076,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ELAN shares. JPMorgan Chase & Co. lifted their price target on Elanco Animal Health from $28.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. UBS Group restated a “buy” rating on shares of Elanco Animal Health in a report on Tuesday, March 10th. Citigroup lifted their target price on shares of Elanco Animal Health from $30.00 to $31.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Piper Sandler reaffirmed an “overweight” rating on shares of Elanco Animal Health in a report on Monday, June 29th. Finally, TD Cowen increased their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $28.55.

Insider Activity

In other news, CEO Jeffrey N. Simmons acquired 4,971 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The stock was purchased at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the transaction, the chief executive officer owned 171,971 shares in the company, valued at approximately $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Rajeev A. Modi bought 4,911 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were purchased at an average cost of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the purchase, the insider directly owned 160,812 shares of the company’s stock, valued at $3,272,524.20. This trade represents a 3.15% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 1.14% of the stock is currently owned by company insiders.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN traded down $0.54 during midday trading on Tuesday, hitting $24.59. The company had a trading volume of 194,051 shares, compared to its average volume of 5,387,346. Elanco Animal Health Incorporated has a twelve month low of $13.39 and a twelve month high of $27.72. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.16 and a quick ratio of 1.12. The stock has a market cap of $12.28 billion, a price-to-earnings ratio of -49.14, a price-to-earnings-growth ratio of 1.63 and a beta of 1.68. The business’s 50-day simple moving average is $23.25 and its 200-day simple moving average is $23.71.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter in the previous year, the company posted $0.37 earnings per share. The firm’s revenue for the quarter was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. On average, research analysts predict that Elanco Animal Health Incorporated will post 1.11 earnings per share for the current year.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.